In a single arm phase I/II trial study evaluating the effects of tremelimumab, a CTLA-4 inhibitor combined with ablative therapies, thirty-two patients with advance HCC received 3.5 and 10 mg/kg tremelimumab IV every 4 weeks for a total of 6 doses followed by 3-monthly maintenance doses. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.